Japan · Delayed Price · Currency is JPY Lion Corporation Earnings Call Transcripts
Fiscal Year 2026
-
Sales and profit exceeded projections in Q2 FY2026, led by strong Oral Healthcare growth and overseas recovery. Despite a JPY 5 billion raw material cost headwind expected in H2, price increases and cost reductions are set to offset impacts, with full-year targets and dividend growth reaffirmed.
-
Strong market positions in Asia are supported by advanced technology and a unique localization strategy. The focus is shifting to high-margin oral healthcare, with targeted investments in premium segments and new markets. Recent acquisitions and organizational changes aim to accelerate profitable growth.
-
Q1 saw solid sales and profit growth, led by oral healthcare and overseas integration, despite rising raw material costs from Middle East risks. Full-year guidance and dividend outlook remain unchanged, with countermeasures in place to offset cost pressures.
Fiscal Year 2025
-
Revenue and profit exceeded guidance for FY 2025, driven by high value-added products and strong overseas performance, especially in Southeast Asia. FY 2026 targets further margin improvement, growth investment, and continued dividend increases.
-
Sales and profit grew year-over-year, driven by new product launches and profitability reforms, with strong domestic performance offsetting overseas challenges. Overseas business remains focused on margin improvement and strategic investments, while organizational restructuring aims to accelerate growth.
-
Revenue and profitability improved year-on-year, driven by structural reforms, high value-added products, and cost efficiencies. Overseas growth remains a key focus, with premium brands performing well in China and Southeast Asia, while risks from China’s slowdown are considered manageable.
-
Sales and profits rose for the first time in four years, driven by strong overseas growth and profit structure reforms. EBITDA margin improved to 10.9%, with targets set for 13%+ by 2027 and continued focus on Oral Healthcare and overseas expansion.